1. Karlsson, et al. J Immunol Methods 1993;166:75 84. 1. Wood et al. Nat Biotechnol 2011. 2. Wood et al. Nat Protoc 2012.
The anaphylatoxin C5a, a potent complement activation product,
the cleavage of C5. Methods: Whole blood (anticoagulated with the
specific thrombin inhibitor lepirudin) from healthy donors (n=7),
exposed to 108 Nm/mL9eculizumab (Soliris†)100 mg/mL for 4 h
(378C) was sequentially centrifuged 2 times (2000 g,15 min, RT).
centrifugation 3 times (17000 g, 30 min, RT). Pelleted MPs were
blood exposed to 108 Nm/mL gave a significant shortening of
the time to clot formation: 303 s999 s (mean9SD) compared with
MPs isolated from unexposed blood: 1015 s9210 s (p=0.001).